In conclusion, the current study indicates that the extended treatment of endostatin combined with PT-DC is able to provide further survival benefits with satisfactory toxicity in previously untreated patients with advanced NSCLC. The gene discussed is COL18A1; the disease is non-small cell lung carcinoma.